• Non-invasive

    OxyPrem uses harmless light (more on NIRS) to determine absolute haemoglobin oxygen saturation in any human tissue.

  • Reusable

    OxyPrem offers a two-year sensor lifetime and high component quality, while substantially reducing waste.

  • Precise

    With its excellent performance in repeated placement and its high reading certainty, OxyPrem achieves new levels in precision.

  • Perfusion independent

    High component quality and advanced algorithms provide consistent readings, also across varying perfusion environments.

  • Comfortable

    Due to OxyPrem's glue-free fixation, skin damage from adhesives is avoided.
    Its very soft silicone hull is made for comfortable wear.

  • Versatile

    OxyPrem can be used in any patient at the risk of hypoxia and on any body part which is at least 30 mm thick.

  • Cost efficient

    Since OxyPrem is reusable, costs are reduced drastically when used routinely or over longer time periods.


Links to publications on OxyPrem and its predecessor devices: 1 , 2 , 3 , 4

OXYPREM NEWS

OxyPrem at ISOTT 2021

July 2021

OxyPrem will be present at the yearly conference of the International Society of Oxygen Transport to Tissue. Dr. Alexander Kalyanov, OxyPrem R&D specialist, and Prof. Martin Wolf, Chairman of the OxyPrem Board, will be speakers.

Dates: Jul 26th - 30th. Link: here.

OxyPrem at FutureHealth 2021

April 2021

OxyPrem's CEO Alexander Nitsch will speak at FutureHealth's discussion table "How Swiss innovators are rethinking patient experience", together with Ancora.ai and Medisanté.

Date & time: Apr 28th, 15:00 CET. Link: here.

OxyPrem at Swiss Nordic Bio 2021

February 2021

OxyPrem will be present at this year's edition of Swiss Nordic Bio. We are looking forward to new contacts and interesting exchange of ideas!

See this link for further information. See you there!

OxyPrem selected for US East Coast Startup Bootcamp

February 2021

The OxyPrem team has secured a spot in Swissnex Boston's US East Coast Startup Bootcamp. This excellent 2-week programme provides lots of valuable resources for young companies intending to expand to the US markets.

Follow Swissnex in Boston and New York on LinkedIn to find out more.

OxyPrem wins another Seal of Excellence

November 2020

For the second time, OxyPrem was awarded the EU Seal of Excellence for outstanding projects.

Once again thank you to the EU!

OxyPrem at Neonatal Emergencies Symposium 2020

November 2020

For the second consecutive year, OxyPrem will be present at Neonatal Emergencies organized by Poznan University of Medical Sciences. The event will take place online on November 27th and 28th and host several very interesting sessions.

Information and registration is available on the official website.

OxyPrem at Swiss Indian Entrepreneurship Day

November 2020

Alexander Nitsch will be a guest speaker at the (online) Swiss Indian Entrepreneurship Day.

The official event link is here.

OxyPrem with booth at Startupdays

October 2020

Together with several other high-impact projects by Wyss Zurich, the OxyPrem team is happy to welcome you at the Wyss pavilion at the Startup Days on October 5th and 6th in Berne, Switzerland!

The official Startupdays website is www.startupdays.ch.

OxyPrem selected for Market Discovery Camp Africa

September 2020

Among numerous applicants, OxyPrem is happy to announce selection for the Market Discovery Camp Africa. The team is excited to get in touch with stakeholders from all over the African healthcare sector.

The official announcement is here.

OxyPrem featured in EU publication

August 2020

The European Union has written a feature article on OxyPrem. It is available in six languages via the following link: CLICK.

Alexander Nitsch to speak at Venture Briefing

June 2020

OxyPrem's CEO Alexander Nitsch has been invited to speak at the upcoming Venture Briefing on June 3rd. The link to the event is here.

OxyPrem wins EU Seal of Excellence

May 2020

OxyPrem was awarded the Seal of Excellence by the European Union's Accelerator program (SME Instrument phase II). This demonstrates that OxyPrem is among the top science startups in Europe.

Thank you to the EU for this strong encouragement!

OxyPrem at Cause of Health

February 2020

The OxyPrem team is attending the LSZ Cause of Health Conference at Technopark Zurich on February 3rd.

The entire team is looking forward to interesting conversations and exciting talks!

OxyPrem at SafeBoosC investigators meeting

January 2020

OxyPrem will be present at the Investigators Meeting of the SafeBoosC-III study held in Copenhagen, Denmark.

The team is happy for the opportunity to meet the leading clinicians from the European neonatology field.

OxyPrem at FutureHealth Basel

January 2020

OxyPrem will be present at the FutureHealth Basel 2020 held on January 28th. Please come and see us at our booth!

Neonatal Emergencies Symposium

November 2019

OxyPrem will attend the Neonatal Emergencies Symposium in Poznan, Poland (details on neonate.eu.

It will be very interesting to exchange ideas with leading Polish and other European neonatologists.

OxyPrem in AIT Brazil

November 2019

OxyPrem is pleased to announce that we have been selected for the 2019/2020 cohort of the St. Gallen University's AIT Brazil programme.

AIT (Academia-Industry Training) Brazil is a two-chapter programme which brings Brazilian and Swiss entrepreneurs together in on-site visits to both countries.

OxyPrem obtains EU support

September 2019

The European Union is supporting OxyPrem by means of its Horizon 2020 SME instrument. Thank you to the EU for their support!

The OxyPrem application was selected for support under phase I of the SME instrument programme following a thorough review by the European Union.

OxyPrem at Swiss Innovation Forum

October 2019

OxyPrem will have a booth at the Swiss Innovation Forum 2019 at Congress Center Basel on Nov 21st.

In its 14th installment, the SIF will the "annual dose of inspiration" to attendees from science, industry and public bodies.

OxyPrem 1.4 gets CE mark

September 2019

The OxyPrem 1.4 tissue oximeter system has obtained the CE mark.

Thus, OxyPrem 1.4 may now be used in professional clinical environments. Our entire team is glad to have achieved this big milestone!

OxyPrem wins Venture Kick

August 2019

The OxyPrem team has successfully completed Venture Kick stage 3. After one year, the Venture Kick journey has come to an end and OxyPrem will receive an additional CHF 100'000.-- in funding.

The official announcement is here.

OxyPrem in MassChallenge and Innosuisse

May 2019

OxyPrem was selected for participation in MassChallenge Switzerland as well as Innosuisse's Core Coaching program.

More info on the programmes is available here and here.

OxyPrem wins Swiss Indian AIT award

April 2019

OxyPrem and our friends from Prediva are the Swiss Winners of the 2018/19 Academia-Industry Training (AIT) India programme.
Thank you to all participants and to Venturelab!

Read more here and here.

OxyPrem enters Wyss Zurich

February 2019

Wyss Zurich is a joint accelerator by University of Zurich and ETH Zurich, made possible by a generous donation by philantropist Dr. h.c. mult. Hansjörg Wyss.

Please visit our profile page here.

Uniscientia supports UZH and OxyPrem

December 2018

The UZH Faculty of Medicine has received a considerable donation by Uniscientia Foundation. It will be used to support OxyPrem.

Thank you for the encouragement from the entire team!

OxyPrem moves on in Venture Kick

November 2018

OxyPrem advances to Venture Kick stage II.

Thanks to the jury for the exciting session and the interesting questions and good feedback.

The official announcement is here.

OxyPrem in top 30 of 178 startups

September 2018

OxyPrem has reached the semifinals in the pitching battle of Startup Days 2018.

This puts OxyPrem on par with the English national team.

OxyPrem goes to India

September 2018

OxyPrem has successfully achieved participation in the VentureLab AIT India programme.

We will take part in a one-week visit to India in December to meet clinicians and industry partners.

OxyPrem gets venture kicked

August 2018

We are now part of Switzerland's well known Venture Kick programme.

Our team successfully completed the stage I pitch and will soon be heading for the "kickers camp" to prepare for stage II and exchange ideas with other founders.

The official announcement is here.

OxyPrem Press Coverage

May 2018

The UZH Annual Media Conference has brought about some press coverage:

For example here, here, here, here, here, and here.

A big thank you to all the journalists for the interesting questions and the good reporting!

Meet OxyPrem at Medtec Europe Stuttgart, April 17th-19th

April 2018

The OxyPrem team is heading for Stuttgart to establish production partnerships.

Please contact us to get in touch at the event.

Find additional information here:
Medtec Europe, Stuttgart 2018

Cooperation with Therapy Development Accelerator

February 2018

The OxyPrem team has started a collaboration with Zurich-based Therapy Development Accelerator (TDA).

The TDA expert team offers a wide range of knowledge, infrastructure, and services to push partnering projects forward.

Visit the TDA website for more information.

OxyPrem team obtains UZH BioEntrepreneur Fellowship

February 2018

Project OxyPrem is now part of the UZH BioEntrepreneur Fellowship program by the University of Zurich.

Find additional information here:
Fellowship information
List of Fellows

OxyPrem to present at Sachs Medtech & Digital Health Forum 2017

Aug 2017

OxyPrem will be part of this year's Rising Stars Start-Up Showcase of the Sachs MedTech & Digital Health Forum in Basel, Switzerland on Sep 25th, 2017.

Find additional information here:
5th Annual MedTech & Digital Health Forum

TEAM

Dr. Fabienne di Gennaro icon-p

Dr. Fabienne di Gennaro

Regulatory Affairs and Quality Manager

icon-m
Dr. Stefan Kleiser icon-p

Dr. Stefan Kleiser

CTO

icon-m
Dr. Alexander Kalyanov icon-p

Dr. Alexander Kalyanov

R&D Specialist

icon-m
Dr. Maximillian Murphy icon-p

Dr. Maximillian Murphy

Software Engineer

icon-m
Alexander Nitsch icon-p

Alexander Nitsch

CEO

icon-m
Anais Nüssli icon-p

Anais Nüssli

Product Designer

icon-m
Daniel Ostojic icon-p

Dr. Daniel Ostojic

Lead Product Development

icon-m
Dr. Kristina Salzer icon-p

Dr. Kristina Salzer

Customer Relations

icon-m
Margrit Teuscher Bernhard icon-p

Margrit Teuscher Bernhard

Business Manager

icon-m
Pieter van der Poel icon-p

Pieter van der Poel

CMO

icon-m
David Vartok icon-p

David Vartok

Cloud Architect

icon-m
Hanneke Verbiest icon-p

Hanneke Verbiest

Clinical Trials and PMS Manager

icon-m
Prof. Martin Wolf icon-p

Prof. Martin Wolf

Chairman of the Board

icon-m

CONTACT OXYPREM

NOTE: OxyPrem is not involved in the organisation of the SafeBoosC-III trial, but provides equipment for multiple participating hospitals. For any questions related to the SafeBoosC-III trial, please contact the SafeBoosC consortium directly via this E-Mail link.

To randomise babies in the SafeBoosC-III trial, please go to this link to Open Clinica.

Dr. Stefan Kleiser

Co-Founder / CTO
+41 76 274 46 75
E-Mail

Alexander Nitsch

Co-Founder / CEO
+41 76 263 87 31
E-Mail


OxyPrem AG
c/o Universität Zürich
Klinik für Neonatologie
Frauenklinikstrasse 10
8091 Zürich (Switzerland)

Switzerland

+41 43 508 34 82
E-Mail

Denmark

+45 78 150 372
E-Mail

Germany

+49 69 967 582 46
E-Mail

Greece

+30 211 176 8286
E-Mail

Poland

+48 22 300 3916
E-Mail

Spain

+34 91 123 36 13
E-Mail

SUPPORTED BY

Venture Kick phase III winner
EU SME phase I winner
Wyss Zurich Project